TrialEuropean heart journal2026

Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.

Brady Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.